EGF-induced YANK2 phosphorylates p70S6K at T389, activates p70S6K to promote cell proliferation, enhances the tumorigenicity of glioma cells, and significantly reduces the survival time of glioma patients. This evidence concerns the gene RPS6KB1 and central nervous system cancer.